Drug prices: in the USA, Pfizer increases by about 9%

Since the beginning of the month, the price of Pfizer's drugs in the US has reportedly increased by around 9%. This is the second increase that the American giant has recorded this year. The increase was disclosed by a Morgan Stanley investor, according to whom the increases would not reflect any discounts.

Since 2012, Pfizer has steadily raised the price of its drugs, increasing revenue by $1.07 billion each quarter. An operation that has allowed the American giant to cope with the entry of generics into the market. In particular, from 1 June Pfizer would have increased the price, in the USA, of 100 of its products, some with a plus 20% on the previous price.

Among the drugs affected so far by the price increases are Lyrica, the cost of which has reportedly increased by 9% on at least one other prior occasion, while the price of Viagra has reportedly increased by 13%. Ibrance, the medicine against cbreast cancer that slows disease progression for at least nine months, saw a price increase of 5%. The drugs that increased the most, however, with an increase in 20%, were the anticonvulsant Dilantin, the hormone therapy Menest, the anti-angina drug Nitrosat, the anti-irregular heartbeat drug Tykosyn, and the antibiotic Tygacil.

June 13, 2016 – Daily Health Industry

Redazione Fedaiisf

Promote the cohesion and union of all members to allow a univocal and homogeneous vision of the professional problems inherent in the activity of pharmaceutical sales reps.

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco